Warning: Declaration of titlemenuwalker::start_el(&$output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/customer/www/diabetesdailypost.com/public_html/wp-content/themes/frailespatique/functions.php on line 30

Warning: Declaration of kohette_combomenu_walker::start_el(&$output, $category, $depth, $args) should be compatible with Walker_Category::start_el(&$output, $category, $depth = 0, $args = Array, $id = 0) in /home/customer/www/diabetesdailypost.com/public_html/wp-content/themes/frailespatique/widgets/kohette-combo-menu.php on line 20

Warning: Use of undefined constant ktt_theme_js - assumed 'ktt_theme_js' (this will throw an Error in a future version of PHP) in /home/customer/www/diabetesdailypost.com/public_html/wp-content/themes/frailespatique/functions.php on line 813
Exploring a New Long-Acting Insulin – What are the Benefits of Toujeo (Insulin Glargine U300)? | Diabetes Daily Post
Exploring a New Long-Acting Insulin – What are the Benefits of Toujeo (Insulin Glargine U300)?

Exploring a New Long-Acting Insulin – What are the Benefits of Toujeo (Insulin Glargine U300)?

toujeoLantus (insulin glargine) has been available since 2000 and has been a cornerstone for insulin therapy for patients with both type 1 and type 2 diabetes. “Basal” insulin like Lantus works by copying the action of the pancreas and providing a background insulin that lasts throughout the day. Traditionally, long acting insulin’s like Lantus (and Levemir, also basal insulin) are supplied in a concentration of U100, or 100 units of insulin per 1 milliliter of injection solution. Recently, however, the FDA approved a more concentrated version of insulin glargine known as Toujeo™. It has a concentration of U300, or 300 units of insulin per 1 milliliter of injection solution. That means it’s 3 times more concentrated than Lantus.

Lantus works by forming a depot of insulin in the fatty layer under the skin after injection. The insulin from this depot is slowly released and absorbed by the body, creating a constant inflow of background insulin throughout the day. The chemical compound of Toujeo is actually identical to the original Lantus compound (both insulin glargine), but, due to some minor modifications, there are significant differences in the way the two medications work. Firstly, Toujeo is absorbed more slowly than Lantus and actually works longer in your body. If you forgot to inject your dose, you can still inject this insulin if you are a few hours late. Secondly, since Toujeo is three times more concentrated than Lantus, the amount of insulin injected is 1/3 the amount to get the same dose of insulin. This is especially important for patients with type 2 diabetes, who tend to inject more insulin than those with type 1 diabetes. There may also be less low blood sugars (hypoglycemia), particularly at night, and less weight gain associated with using Toujeo. Both Toujeo and Lantus are equally effective in reducing blood sugar levels.

Toujeo is available in a pen form only;not a vial. Each Toujeo Solostar pen carries 450 units of insulin (150 more units than the Lantus version) and can deliver up to 80 units of insulin per injection. Both Toujeo and Lantus are dosed in units and not milliliters, so if converting from another basal insulin such as Lantus or Levemir the dose is the same. Using the Solostar pen, you just dial to the dose (in units) that you need and the pen automatically delivers the correct volume and units.Similar to Lantus, the Toujeo Solostar pen is good for 28 days outside of the refrigerator after the first use. Pens not being used should be stored in the refrigerator.

Toujeo may be a good option in those patients that currently inject basal insulin twice a day, as this can be given once a day in a smaller volume, with less nighttime hypoglycemia and less weight gain. It is a good option to add on to oral drug therapy in patients with type 2 diabetes who would benefit from the addition of background insulin.

This article is brought to yo by our guest writers:
Damian Bialonczyk, PharmD, MBA, Medical Affairs Fellow, Becton Dickinson, MCPHS University
KevorkOurfalian, PharmD, Medical Affairs Fellow, Becton Dickinson, MCPHS University
Jennifer Goldman, PharmD, CDE, BC-ADM, FCCP, Professor of Pharmacy Practice, School of Pharmacy-Boston, MCPHS University, Boston, MA, Clinical Pharmacist, Well Life Medical, Peabody, MA

No comments

You must be logged in to post a comment.